Abstract Renal cell carcinomas (RCC) comprise multiple molecularly distinct cancers but most are treated empirically with therapies designed for clear cell RCC (ccRCC), the most common subtype, due to incomplete understanding of subtype-specific biology. We analyzed single-cell transcriptomes and chromatin accessibility profiles from translocation renal cell carcinoma (tRCC), an aggressive RCC defined by oncogenic TFE3 gene fusions.
David Einstein
As seen in:
Forbes,
Nature,
Wiley Online Library,
Harvard Health Publishing,
Entrepreneur,
SFGate,
JAMA Oncology,
Medscape,
OncLive,
European Urology
and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by David Einstein
Biochemical Recurrence in Prostate Cancer: What It Means and What Comes Next
This transcript has been edited for clarity. Hi. My name is David Einstein. I am a medical oncologist at Beth Israel Deaconess Medical Center and Dana-Farber Cancer Institute. I lead the genitourinary oncology group at Beth Israel. I'm really excited to be here with you today to talk a little bit about biochemical recurrence, which, to me, is one of the most exciting and most confusing areas in all of prostate cancer.
FOXJ1 mediates taxane resistance through regulation of microtubule dynamics - Nature Communications
Abstract Docetaxel is the first-line chemotherapy for metastatic prostate cancer (PC), but clinically meaningful mechanisms of resistance remain to be established. Here we show, in an in vivo model of docetaxel resistant PC patient-derived xenografts, increased expression of genes that drive development of multiciliated cells including FOXJ1 and its effectors, many of which regulate microtubules (MTs).
National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations
Authors' Disclosures of Potential Conflicts of Interest The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.
Long-term Outcomes and Prognostic Impact of Residual Cancer Burden After Intensified Neoadjuvant Therapy in High-risk Prostate Cancer
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aDana-Farber Cancer Institute Boston MA USA bIndiana University Indianapolis IN USA cBeth Israel Deaconess Medical Center Boston MA USA dUniversity of California-San Diego CA USA eBrigham & Women's Hospital, MA, USA Publication History: Accepted January 19, 2025;...
How to Break Out of AI Analysis Paralysis Original
It's a case study of the dangers of overthinking. Many businesses are getting stuck trying to solve complex problems with AI instead of focusing on obvious opportunities where it could provide value very quickly. It comes back to the fundamental way the leaders of those companies perceive artificial intelligence — is it a tool or a threat? Part of the problem is that people are aware that AI can do a lot.
Metastasis-Free Survival Versus Treatment-Free Survival in Biochemically Recurrent Prostate Cancer: The EMBARK Trial
Serum tumor markers can be a blessing and a curse. After definitive local therapy for prostate cancer, prostate-specific antigen (PSA) is quite sensitive and specific, and can detect micrometastatic disease well before any radiographic or symptomatic evidence of disease. When biochemical recurrence (BCR) occurs, early detection can guide curative-intent salvage therapies such as salvage radiation.
Council Post: The Marketing Leader's Guide To Search Generative Experience In 2024
As Co-founder of Orange Line, a global marketing consulting firm, my sole focus is to drive profitable growth for your business. Google’s planned release of the AI-driven system called Search Generative Experience (SGE) is set to drastically change the world of search, both organic and paid, including how we perform SEO, measure it, and its benefits. The ramifications, from the future of Google’s business model to the nature of the web itself, are complex and difficult to predict.
Council Post: How To Scale Profits Safely With AI
As Co-founder of Orange Line, a global marketing consulting firm, my sole focus is to drive profitable growth for your business. Artificial intelligence as a tool is like nunchucks as a weapon—they look cool and can help you take out 10 people at once, but unless you know what you’re doing when wielding them, they can end up giving you a black eye. AI can help you get somewhere really fast, but that might be very far from where you actually want to be.
Postradical prostatectomy prostate‐specific antigen outcomes after 6 versus 18 months of perioperative androgen‐deprivation therapy in men with localized, unfavorable intermediate-risk or high‐risk prostate cancer: Results of part 2 of a randomized phase
CONFLICT OF INTEREST STATEMENT Rana R.
Palliative care frightens some people: Here’s how it helps
Diseases & Conditions During many stages of illness, palliative care can ease strains and provide additional support. September 14, 2022 By Emily Stern Gatof, MD, Guest Contributor, and David J. Einstein, MD, Contributor Many people and their families associate the term palliative care with the end of life. Some may think that palliative care and hospice care are one and the same.
Metastatic Castration-Resistant Prostate Cancer Remains Dependent on Oncogenic Drivers Found in Primary Tumors
Localized prostate cancer (PC) can be curable, but metastatic recurrence is unfortunately common. Metastatic PC is initially sensitive to androgen receptor (AR) inhibition, but eventually becomes castration-resistant (mCRPC). Early use of more intensive therapies targeting AR and other oncogenic drivers may be more effective than in advanced mCRPC.
Patient Perceptions of Treatment Benefit and Toxicity in Advanced Cancer: A Prospective Cross-Sectional Study
PURPOSE: Prior studies show that many patients receiving palliative cancer therapies misperceive likelihood of cure. Patients’ understanding of treatment benefits and risks beyond cure is unknown. We explore patient perceptions of palliative treatment in the novel therapeutic era. METHODS: We surveyed patients with advanced solid cancers and their oncologists regarding benefits and risks of palliative therapies.
The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer
Siegel R.L. Miller K.D. Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020; 70: 7-30 Roehl K.A. Han M. Ramos C.G. et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol. 2004; 172: 910-914 Freedland S.J. Humphreys E.B. Mangold L.A. et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA.
Against “Healthy Paternalism” at the End of Life-Reply
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
BITE-SIZE REVIEWS
To sample the flavor of current corporate feeding trends, Chronicle reporters visited 14 cafeterias from Marin to Mountain View, and from San Francisco to San Ramon. Here are morsels from their visits. .
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with David
Contact David, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack